Month: November 2025
Excerpt from the Press Release: BOSTON and SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, Pte. Ltd, a biotechnology company developing next-generation T…
First Gene Therapy Trial for Angelman Syndrome -Orphan Drug Designation Granted for MVX-220 Excerpt from the Press Release: MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2…
Program derived from Montai’s Anthromolecule chemistry demonstrates potent selectivity and efficacy against a triad of key mechanisms implicated in UC Company’s first development candidate to advance to IND-enabling studies Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Montai Therapeutics, a company harnessing AI to decode untapped, diverse chemistry to develop breakthrough medicines for chronic disease, will…
Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board’s Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment Strategies Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies…
The Implantable Cell Therapy AVB-114 Demonstrated Favorable Safety and Effectiveness in the Phase II Trial for Crohn’s Perianal Fistulas – Excerpt from the Press Release: NEWARK, Del., Oct. 29, 2025 /PRNewswire/ — Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced that the STOMP2 primary analysis results were revealed today at a…
Favorable early safety profile with preliminary clinical and mechanistic evidence of therapeutic activity in refractory rheumatoid arthritis Data to be presented in a late-breaking oral presentation today 8:00 a.m. CT at the 2025 American College of Rheumatology (ACR) Convergence Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & SEATTLE–(BUSINESS WIRE)–Sonoma Biotherapeutics, Inc., a clinical-stage…
Excerpt from the Press Release: WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose…
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in…
CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial…
- « Previous
- 1
- 2
- 3
- Next »